...
首页> 外文期刊>Applied Microbiology and Biotechnology >Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets?
【24h】

Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets?

机译:细胞色素P450酶的功能,基础和表达及其在结核分枝杆菌中的同源氧化还原伴侣:他们是药物靶标吗?

获取原文
获取原文并翻译 | 示例

摘要

This review covers the current knowledge of the cytochrome P450 enzymes (CYPs) of the human pathogen Mycobacterium tuberculosis (Mtb) and their endogenous redox partners, focusing on their biological function, expression, regulation, involvement in antibiotic resistance, and suitability for exploitation as antitubercular targets. The Mtb genome encodes twenty CYPs and nine associated redox partners required for CYP catalytic activity. Transposon insertion mutagenesis studies have established the (conditional) essentiality of several of these enzymes for in vitro growth and host infection. Biochemical characterization of a handful of Mtb CYPs has revealed that they have specific physiological functions in bacterial virulence and persistence in the host. Analysis of the transcriptional response of Mtb CYPs and redox partners to external insults and to first-line antibiotics used to treat tuberculosis showed a diverse expression landscape, suggesting for some enzymes a potential role in drug resistance. Combining the knowledge about the physiological roles and expression profiles indicates that, at least five Mtb CYPs, CYP121A1, CYP125A1, CYP139A1, CYP142A1, and CYP143A1, as well as two ferredoxins, FdxA and FdxC, can be considered promising novel therapeutic targets.
机译:本综述涵盖了目前的知识,即人病原体结核分枝杆菌(MTB)和其内源性氧化还原伴侣的细胞色素P450酶(CYP),重点关注其生物学功能,表达,调节,抗生素抗性的参与,以及剥削作为抗度剥削的适合性目标。 MTB基因组编码CYP催化活性所需的20个Cyps和九个相关的氧化还原合作伙伴。转座子插入诱变研究已经建立了用于体外生长和宿主感染的几种这些酶的(条件)的物质。少数MTB Cyps的生化表征揭示它们具有细菌毒力和持久性的特异性生理功能。分析MTB CYPS和氧化还原合作伙伴对外部侮辱和用于治疗结核病的一线抗生素的转录响应显示出一种不同的表达景观,表明一些酶在耐药性中的潜在作用。组合关于生理角色和表达谱的知识表明,至少五种MTB CYPS,CYP121A1,CYP125A1,CYP139A1,CYP142A1和CYP143A1以及两个富勒氏蛋白,FDXA和FDXC,可被认为是有前途的新的治疗目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号